Trial Profile
An Observational Study of Cardiovascular Complications of Carfilzomib Treatment in Clinical Practice
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 27 Apr 2021 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Status changed from recruiting to active, no longer recruiting.